Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
Total Page:16
File Type:pdf, Size:1020Kb
Research Article Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Alison Maloney,1 Paul A. Clarke,1 Soren Naaby-Hansen,3,4 Rob Stein,3,5 Jens-Oliver Koopman,3,4 Akunna Akpan,3,4 Alice Yang,3,4 Marketa Zvelebil,3,4 Rainer Cramer,3,4 Lindsay Stimson,1 Wynne Aherne,1 Udai Banerji,1,2 Ian Judson,1,2 Swee Sharp,1 Marissa Powers,1 Emmanuel deBilly,1 Joanne Salmons,1 Michael Walton,1 Al Burlingame,3,4 Michael Waterfield,3,4 and Paul Workman1 1Haddow Laboratories, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 2Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 3Ludwig Institute for Cancer Research and Departments of 4Biochemistry and Molecular Biology and 5Oncology, University College London, London, United Kingdom Abstract anticancer agents and provide a means of obtaining a detailed The promising antitumor activity of 17-allylamino-17-deme- molecular signature of drug action (1, 2). In addition, these thoxygeldanamycin (17AAG) results from inhibition of the methods may identify pharmacodynamic markers that can be used molecular chaperone heat shock protein 90(HSP90)and to evaluate drugs in clinical trials. Gene expression microarrays are subsequent degradation of multiple oncogenic client proteins. increasingly used to investigate the molecular responses to cancer Gene expression microarray and proteomic analysis were used drugs in tumor cells (1). Although valuable, analysis of gene to profile molecular changes in the A2780human ovarian expression at the mRNA level alone cannot adequately predict cancer cell line treated with 17AAG. Comparison of results protein expression or functional states. Therefore, proteomic with an inactive analogue and an alternative HSP90inhibitor approaches also have considerable potential in the drug develop- radicicol indicated that increased expression of HSP72, ment process (2). Heat shock proteins (HSPs) are a major class of molecular HSC70, HSP27, HSP47, and HSP90B at the mRNA level were on-target effects of 17AAG. HSP27 protein levels were chaperones that play a vital role in the cellular stress response increased in tumor biopsies following treatment of patients and cancer (3, 4). One particular chaperone, HSP90, is of with 17AAG. A group of MYC-regulated mRNAs was decreased considerable current interest as a new cancer therapeutic target by 17AAG. Of particular interest and novelty were changes because of its essential role in maintaining the conformational in expression of chromatin-associated proteins. Expression of stability and function of a number of oncogenic ‘‘client’’ proteins the heterochromatin protein 1 was increased, and expression that are required for cellular proliferation, cell cycle regulation, of the histone acetyltransferase 1 and the histone arginine apoptosis, invasion, angiogenesis, and metastasis (for review, see methyltransferase PRMT5 was decreased by 17AAG. PRMT5 refs. 4, 5). The natural product HSP90 inhibitors radicicol, was shown to be a novel HSP90-binding partner and potential geldanamycin, and their derivatives exert their antitumor effect by inhibiting the intrinsic ATPase activity of HSP90, resulting in client protein. Cellular protein acetylation was reduced by 17AAG, which was shown to have an antagonistic interaction degradation of HSP90 client proteins via the ubiquitin-protea- on cell proliferation with the histone deacetylase inhibitor some pathway (4, 5). Based on its novel mechanism of action trichostatin A. This mRNA and protein expression analysis has and the potential for combinatorial effects on multiple provided new insights into the complex molecular pharma- oncogenic pathways and on all of the hallmarks of cancer (6), cology of 17AAG and suggested new genes and proteins that together with promising therapeutic effects in animal models may be involved in response to the drug or be potential (e.g., refs. 7–9), the geldanamycin analogue 17-allylamino-17- biomarkers of drug action. [Cancer Res 2007;67(7):3239–53] demethoxygeldanamycin (17AAG), a benzoquinone ansamycin, has completed phase I and is now in phase II clinical trials as the first-in-class HSP90 inhibitor (10, 11). Other HSP90 inhibitors Introduction are also in development (5). Gene expression microarray and proteomic profiling facilitate Gene expression profiling studies have been done previously in screening for the response of thousands of mRNAs and proteins to a panel of human colon cancer cell lines following treatment with 17AAG (12). That study identified HSC70 (HSPA8) and HSP90b (HSPCB) as 17AAG-responsive genes (12). Alongside depletion in Note: Supplementary data for this article are available at Cancer Research Online levels of client proteins, such as c-RAF-1 and cyclin-dependent (http://cancerres.aacrjournals.org/). kinase 4 (CDK4), inducible HSP72 (HSPA1A/HSPA1B) has been P. Workman is a Cancer Research UK Life Fellow. Conflict of interest: P. Workman’s laboratory has received support from Vernalis, used as a pharmacodynamic end point in phase I clinical trials of and HSP90 inhibitor technology from The Institute of Cancer Research/Vernalis 17AAG (e.g., ref. 10). Indeed, this basic molecular signature has collaboration has been licensed to Novartis. Requests for reprints: Paul Workman, Haddow Laboratories, Cancer Research been used to show HSP90 inhibition in the tumor tissue of UK Centre for Cancer Therapeutics, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 treated patients, and this was associated with prolonged stable 5NG, United Kingdom. Phone: 44-20-8722-4301; Fax: 44-20-8722-4324; E-mail: paul. disease in two patients with metastatic malignant melanoma (10). [email protected]. I2007 American Association for Cancer Research. The cellular response to HSP90 inhibition has a complex nature doi:10.1158/0008-5472.CAN-06-2968 that involves both multiple protein changes and effects on www.aacrjournals.org 3239 Cancer Res 2007; 67: (7). April 1, 2007 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 2007 American Association for Cancer Research. Cancer Research transcription. We hypothesized that by using proteomic analysis obtained from Sigma Chemical Co. (Poole, United Kingdom). Compounds in combination with gene expression microarray profiling we were stored as 2 mmol/L stocks in DMSO at À20jC and protected from might identify additional molecular responses to 17AAG that light. All reagents were from Sigma unless stated otherwise and were of would increase our understanding of the mechanism of action of highest chemical grade. the drug. This approach also has the potential to facilitate the Combination treatments. A2780 cells were seeded at 1,000 per well in 96-well plates. Sulfurhodamine blue staining was used to determine the IC discovery of new HSP90 client proteins as well as to suggest novel 50 at 96 h for TSA and 17AAG. These values were then used in combination pharmacodynamic markers. studies according to the median effect analysis method of Chou and Talalay We now report a study in which the complementary (13). Briefly, increasing concentrations of TSA and 17AAG were added at a approaches of mRNA and protein expression profiling have been ratio of 1:1 based on their respective IC50 values. Following a 96-h exposure, used in parallel to examine expression changes in response to cells were stained with sulfurhodamine blue, and a combination index for drug treatment in a human cancer cell line. Changes in mRNA nonexclusive interactions was calculated using an algorithm based on that and protein expression were determined following treatment of described by Chou and Talalay (13). A combination index of 1 indicates an a human ovarian adenocarcinoma cell line with 17AAG. In additive interaction; a combination index < 1 indicates a synergistic addition, we sought to distinguish ‘‘on-target’’ effects (those which interaction; and a combination index > 1 indicates an antagonistic are a consequence of HSP90 inhibition) from ‘‘off-target’’ effects interaction. Protein extraction. A2780 cells were plated in 75-cm2 dishes at a (those which relate to other interactions) by comparison of the density of 1 Â 106 and left to attach for 24 h. Control cells were set up in molecular responses obtained following treatment with 17AAG quadruplicate, and 17AAG-treated cells set up in duplicate. Additional with those seen with the chemically dissimilar HSP90 inhibitor dishes were set up for cDNA microarray and Western blotting analysis. radicicol or an inactive analogue of 17AAG. Selected known and Cells were treated for 24 h with pharmacologically relevant, isoeffective novel expression changes were followed up by validation using concentrations of 17AAG (60 nmol/L) and radicicol (600 nmol/L), or, in Western blotting and investigation of functional and therapeutic some experiments, with an equimolar concentration of the inactive significance. 17AAG analogue and radicicol in relation to 17AAG (60 nmol/L) in 10 mL Expression profiling studies revealed that around 3% of the medium. total gene transcripts examined and 4% of the detectable proteins Cell lysates for proteomic analysis were prepared in a laminar flow were responsive to 17AAG treatment. The changes seen involved hood by scraping the cells into lysis buffer containing 8 mol/L urea (Merck, Poole, United Kingdom), 2 mol/L thiourea (Merck), 4% CHAPS, 65 a number of molecular chaperones, protein synthesis and degra- mmol/L DTT (Merck), and a protease